Multicentre, randomised, double-blind, placebo-controlled, proof of concept study of LSALT peptide as prevention of acute respiratory distress syndrome and acute kidney injury in patients infected with SARS-CoV-2 (COVID-19).
Ranjani SomayajiDavid R LukeArthur LauRahmet GunerŎ Fehmi TabakMark HepokoskiNancy GardettoSteven A ConradSunil D KumarKalyan GhoshStephen M RobbinsDonna L SengerDaisy SunRachel K S LimJonathan LiuFatma EserRidvan KaraaliAlain TremblayDaniel A MuruvePublished in: BMJ open (2024)
NCT04402957.
Keyphrases
- double blind
- placebo controlled
- sars cov
- acute respiratory distress syndrome
- clinical trial
- study protocol
- end stage renal disease
- extracorporeal membrane oxygenation
- phase iii
- ejection fraction
- newly diagnosed
- mechanical ventilation
- coronavirus disease
- chronic kidney disease
- respiratory syndrome coronavirus
- peritoneal dialysis
- open label
- phase ii study
- randomized controlled trial
- prognostic factors
- squamous cell carcinoma
- intensive care unit
- cross sectional
- radiation therapy
- patient reported